When Your Device Might Not Be a Device: Borderline Cases
A manufacturer submits a Class IIa technical file. Six months into the review, the Notified Body suspends the assessment. The reason? The product might not qualify as a medical device at all. This happens more often than you would expect, and it almost always traces back to the same misunderstanding at the boundary between device, drug, cosmetic, and biocide.
In This Article
Borderline products sit at the intersection of multiple regulatory frameworks. The stakes are high because choosing the wrong classification path means the entire regulatory strategy collapses. The MDR does not regulate in isolation. When a product contains substances or relies on mechanisms that overlap with medicinal products, cosmetics, or biocides, you must determine which framework applies first.
This is not an academic exercise. It determines your entire development and regulatory timeline. And when manufacturers get it wrong, the consequences appear late in the process, often during Notified Body review or market surveillance.
Why Borderlines Emerge in the First Place
The MDR defines a medical device primarily by its intended purpose. If the manufacturer intends the product to diagnose, prevent, monitor, treat, or alleviate disease or injury—and if it achieves this purpose through physical, mechanical, or other non-pharmacological means—it may qualify as a device.
But the definition also contains exclusions. Article 1(6) of the MDR explicitly states that certain products are not medical devices even if they meet the general definition. This includes products where the principal intended action is achieved by pharmacological, immunological, or metabolic means.
The boundary becomes difficult when:
- A device incorporates a medicinal substance as an ancillary part
- A product achieves its effect through a combination of physical and pharmacological action
- The intended purpose overlaps with cosmetic claims
- The product is applied to intact skin and the line between cosmetic and therapeutic becomes unclear
Each case requires a detailed analysis of the product’s mode of action, intended purpose, and primary mechanism.
The primary mechanism of action determines the regulatory framework. Not the product form. Not the delivery method. Not what the manufacturer calls it. The mechanism matters most.
Device or Medicinal Product: The Principal Action Test
The most common borderline case involves products that contain both device and drug elements. Article 1(8) of the MDR addresses devices incorporating medicinal substances. These remain medical devices if the substance has an ancillary role and the device achieves its principal intended action by non-pharmacological means.
This sounds straightforward until you try to apply it. What does
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
